Phase 2 Endometrial Cancer Trial, Recruiting NCT07051486 Sponsor: Jiangsu HengRui Medicine Co., Ltd. Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 2 Endometrial Cancer Trial, Recruiting

NCT07051486
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to take part voluntarily, sign a consent form, follow the study requirements, and attend follow-up appointments
  • Women aged 18 to 75 years old (inclusive) at the time of signing the consent form
  • People who have been diagnosed with cervical cancer, confirmed through a tissue or cell sample test
  • People whose doctors expect them to live for at least 12 weeks
  • People whose major organs (such as the liver, kidneys, and heart) are functioning normally
  • Women who could become pregnant must have a negative pregnancy blood test within 7 days before starting the trial treatment, must not be breastfeeding, and must agree to use contraception from signing the consent form until 7 months after the last dose of the trial drug

Who may not be able to join:

  • People who have cancer that has spread to the brain or spinal cord and has not been treated or is currently active
  • People who have had, or currently have, another type of cancer (other than cervical cancer)
  • People who have a significant build-up of fluid around the lungs, heart, or abdomen that is causing symptoms or is difficult to control
  • People who have a history of scarring or inflammation of the lung tissue (interstitial lung disease) that required steroid treatment
  • People who have an autoimmune, connective tissue, or inflammatory condition that affects the lungs
  • People who have known lung damage caused by another existing lung condition
  • People who currently have active tuberculosis (TB) affecting the lungs
  • People who have poorly controlled or serious heart or blood vessel disease
  • People who have had a blood clot in an artery or vein within 1 month before joining the trial
  • People who have had a serious infection within 1 month before joining the trial
  • People who have a weakened immune system, including those who have tested positive for HIV

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-0518-82342973

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Registry
ClinicalTrials.gov
Start date
11 October 2025
Est. completion
1 February 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective response rate (ORR) assessed by Independent Review Committee (IRC)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov